Related Experiment Videos
Depressive symptoms during buprenorphine treatment of opioid abusers
T R Kosten1, C Morgan, T A Kosten
1Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Journal of Substance Abuse Treatment
|January 1, 1990
Abstract:
Among 40 opioid addicts treated as outpatients with sublingual buprenorphine (2-8 mg daily) for a month, depressive symptoms significantly decreased in the 19 who were depressed at intake to treatment.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
GW240925 and GW250207: Astrophysical Calibration of Gravitational Wave Detectors.
Physical review letters·2026
The evidence for neonatal arginine supplementation - A narrative review.
Early human development·2025
The victimisation experience schedule: contextualising interpersonal trauma and perceived discrimination in individuals with psychotic experiences with and without a need-for-care.
Social psychiatry and psychiatric epidemiology·2025
Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.
Psychological medicine·2024
A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
Journal of substance abuse treatment·2022
Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing.
Journal of substance abuse treatment·2022
An intervention pilot to facilitate harm reduction service decentralization in Vietnam.
Journal of substance abuse treatment·2022
Housing and supportive services for substance use and self-efficacy among young mothers experiencing homelessness: A randomized controlled trial.
Journal of substance abuse treatment·2022
Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials.
Journal of substance abuse treatment·2022
Trends in diagnosis of amyloid kidney disease in people who inject drugs (PWID).
Preventive medicine reports·2026
Thiazole-Substituted Benzoylpiperazines with Anti-Cancer and Anti-Inflammatory Activities: Comparative Evaluation with Lercanidipine.
International journal of molecular sciences·2026